Marker Therapeutics said its experimental T-cell therapy MT-601 produced a 66% objective response rate, including 50% complete responses, in Non-Hodgkin Lymphoma patients enrolled in the Phase 1 APOLLO study. The open-label trial has treated 24 heavily pre-treated B-cell lymphoma patients at seven U.S. sites, with doses ranging from 100 million to 400 million cells. Among nine Hodgkin Lymphoma patients, the investigational therapy achieved a 78% overall response rate. Across all dose levels no dose-limiting toxicities, immune-effector cell-associated neurotoxicity syndrome or serious adverse events were reported; only two mild cases of cytokine release syndrome occurred. After clearing the highest dose, the study will move into a dose-expansion phase that will evaluate MT-601 at 400 million cells in patients with diffuse large B-cell lymphoma who have relapsed after, or are ineligible for, CAR-T treatment. A further data update is expected in the first half of 2026.